Rising serum potassium and creatinine concentrations after prescribing renin-angiotensin-aldosterone system blockade: how much should we worry?  

作　　者：Farahnak Assadi 

机构地区：[1]Division of Nephrology,Department of Pediatrics,Rush University Medical Center,445 E.North Water Street,Suite 1804,Chicago,IL,USA

出　　处：《World Journal of Pediatrics》2021年第5期552-554,共3页世界儿科杂志（英文版）

摘　　要：Renin-angiotensin-aldosterone system(RAAS)blockade is often the first-line medication for treating pediatric and adult patients with hypertension,especially those with preexisting chronic kidney disease(CKD)[1,2].However,the rise in serum creatinine and potassium concentrations following RAAS blocked may pose therapeutic challenges whether it is safe to treat hypertensive patients with CKD,by inhibiting[3].Thus,many clinicians neglect to use angiotensin-converting enzyme inhibitor(ACEI)or angiotensin receptor blockade(ARB)especially in patients with CKD because of fear in either reduction of glomerular filtration rate(GFR)or elevation in serum creatinine and potassium concentrations.

关 键 词：CREATININE ALDOSTERONE HYPERTENSIVE 

分 类 号：R726.9[医药卫生—儿科]